• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MSC.Software Corporation

MSC.Software Corporation

  1. BioCardia Announces Publication of 12-Month Results from Phase II TRIDENT Clinical Trial That Shows Positive Safety Profile for Allogeneic Bone Marrow Stem Cells Delivered with Helix Transendocardial ...

    BioCardia Announces Publication of 12-Month Results from Phase II TRIDENT Clinical Trial That Shows Positive Safety Profile for Allogeneic Bone Marrow Stem Cells Delivered with Helix Transendocardial Delivery System

1

©2017 Morningstar Advisor. All right reserved.